The study demonstrates successful gene therapy for maple syrup urine disease

A study that led Umass Chan researchers showed that a gene therapy to correct a mutation that causes urine disease of the syrup of maplendam (MSUD) prevented newborn death, normalized growth, restored and coordinated expression and infected expression.

Simply put, we believe that the gene therapy proved to be in both animal species, especially in cow, projects very well the therapeutic potential for MSUD, in part because the weak cow, without treatment, has a very similar metabolic profile such as patients. “

Dan Wang, PhD, Assistant Professor of Genetics & Cell Medicine

Dr. Wang is a compatriot researcher with Heather Gray-Edwards, DVM, PhD, Assistant Professor of Genetics & Cell Medicine. Guangping Gao, Phd, the Penelope Rockwell Chair booth in biomedical researchDirector of the Horae Gene therapy Center, Director of the Li Weibo Institute for Rare Disease Research and President and Professor of Genetics and Cell Medicine. and Kevin Strauss, MD, Assistant Professor of Pediatrics and Head of Therapeutic Development at Clinic for special children in Gordonville, Pennsylvania.

The study, published in The translation medicine of scienceIt was partially funded through an agreement with ASC Therapeutics, a private biopharmaceutical company that develops in-vivo genes replacement, gene processing and allogeneic cell therapies.

MSUD is a rare genetic inherent metabolism error characterized by repeated life -threatening neurological crises and progressive brain damage that can only be treated with an accurate prescription diet or liver transplantation.

The situation appears in one in 197.714 live births, but it is much more common in some areas of Brazil, Portugal, Turkey, the Philippines and among the people of Ashkenazi or Mennonite descent. Among the population of Mennonite, such as communities in the Lancaster County, Pennsylvania, the incidence of MSUD is one in 400.

MSUD is caused when a mutated form of the BCDHA, BCKDHB or DBT gene is inherited by both parents. As a result of this mutation, the body is not able to break certain parts of the proteins. This leads to the accumulation of toxic substances that can cause organ damage and brain.

The researchers of the current study designed a recombinant serving 9 serum 9 of the adenos-related virus to provide gene replacement to the liver, muscles, heart and brain. They wrote that a lump sum heal has a promise as a therapeutic alternative to recipe diet and liver transplantation for the treatment of Msud types 1a and 1b, the two most common msud forms in humans.

Beef data is more directly translated into humans for the purposes of understanding pharmacokinetics, the specific effects of muscle tissue and brain tissue and long -term durability through an extensive phase of development.

“We believed that gene therapy could be an important discovery for patients with MSUD and, in August 2018, met on a bovine farm in Iowa to follow this vision: to develop and test gene therapy in a unique animal model, a newborn model. “In the years that followed, doctors at the clinic for special children worked carefully with scientists and veterinarians from the Umass Chan Medical School to achieve this goal, drawing their inspiration from the hopes and struggles of the Msud community.

Wang said that the researchers are investigating the American Food and Drug Administration the next steps to translate this gene therapy into clinical use as a Phase I/II study.